Alibaba signs $1.4 billion affiliate deal to get into the medical market
Select language to see a machine translation of this article. The original language of the Article is English and the translation is provided for your convenience.

Alibaba signs $1.4 billion affiliate deal to get into the medical market

Chinese Ecommerce giant Alibaba has signed a new deal that, it hopes, will forward its ambitions in the medical retail world. The company will sell assets (ranging from drugs to medical devices) to a Hong Kong-listed affiliate which will become its flagship healthcare arm.

It revealed the news on Tuesday, saying it would “inject a plethora of businesses” into Alibaba Health Information Technology Ltd., in exchange for $1.4 billion of new stock in the venture. This will give Alibaba a suitable home for things like its Tmall pharmacy, and it will retain 67.5% voting rights.

Alibaba’s share price is up 13% over the last 30 days

graph 3105 alibaba

SOURCE: Yahoo Finance

Alibaba is making a strong play for the state-dominated Chinese healthcare sector. It’s aiming to “transform an outmoded model with data and cloud computing”. This market is worth around 4.6 trillion yuan (about $720 billion, at current exchange rates), and is just one of many disparate areas that Alibaba has been focusing on.

Daniel Zhang, the company’s CEO, made the following comment in a statement: “Healthcare is a strategically important area for Alibaba Group with strong growth potential. This transaction is a logical evolution for the continued development of Alibaba Health into our healthcare flagship platform.”

The deal, which will see Alibaba own 56.2% economic interest and 67.5% voting interest, is still subject to the approval of independent Alibaba Health shareholders and the Hong Kong Stock Exchange.


Dominion holds Alibaba in its Global Trends Ecommerce Fund.

If you would you like to receive the Newsfeeds daily, please click here to sign up now!

Help us make this Newsfeed better by rating this article. 1 star = Poor and 5 stars = Excellent
0.0/5 rating (0 votes)

The views expressed in this article are those of the author at the date of publication and not necessarily those of Dominion Fund Management Limited. The content of this article is not intended as investment advice and will not be updated after publication. Images, video, quotations from literature and any such material which may be subject to copyright is reproduced in whole or in part in this article on the basis of Fair use as applied to news reporting and journalistic comment on events.